CAFFEINE AS A CARDIOPROTECTIVE AND CARDIOTOXIC AGENT: A REVIEW OF RECENT EVIDENCE

Magdalena Kossmann; Laura Szalewska; Amin Abdulgater; Paulina Osuch-Tomaszewska; Wiktoria  Urowska; Jędrzej Łysiak; Izabela Kazubek-Fuksiewicz

doi:10.31435/ijitss.2(50).2026.5440

Authors

Magdalena Kossmann St. Vincent de Paul Hospital, Gdynia, Poland https://orcid.org/0009-0003-2822-6669
Laura Szalewska University Clinical Hospital No. 2, Szczecin, Poland https://orcid.org/0000-0002-9529-7593
Amin Abdulgater University Clinical Hospital No. 2 PMU, Szczecin, Poland https://orcid.org/0009-0000-3782-5776
Paulina Osuch-Tomaszewska University Clinical Hospital No. 2, Szczecin, Poland https://orcid.org/0009-0002-4204-0273
Wiktoria Urowska St. Vincent de Paul Hospital, Gdynia, Poland https://orcid.org/0009-0000-4167-4798
Jędrzej Łysiak University Clinical Hospital No. 2, Szczecin, Poland https://orcid.org/0009-0005-5798-3620
Izabela Kazubek-Fuksiewicz Medical University of Silesia in Katowice, Katowice, Poland https://orcid.org/0009-0000-4433-2638

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5440

Keywords:

Caffeine, Coffee, Cardiovascular Health, Arrhythmias, Heart Failure, Energy Drinks

Abstract

Caffeine is the most widely consumed psychoactive substance worldwide and is ingested daily in coffee, tea, cocoa, energy drinks, and dietary supplements. Its cardiovascular effects remain controversial because both beneficial and harmful associations have been reported. This review synthesizes recent evidence on the cardioprotective and cardiotoxic effects of caffeine, with particular attention to dose-response relationships, habitual versus acute exposure, product type, arrhythmias, blood pressure, heart failure, endothelial function, and genetic variability in caffeine metabolism. Available evidence from large cohort studies and reviews indicates that moderate habitual intake, particularly from traditional coffee consumption, is generally associated with a favorable cardiovascular profile, including lower cardiovascular and all-cause mortality and a lower risk of incident heart failure in some populations (Chieng et al., 2022; Poole et al., 2017; Stevens et al., 2021). Moderate intake does not appear to increase atrial fibrillation risk in the general population and may be neutral or modestly favorable in observational studies (Caldeira et al., 2013; Cheng et al., 2014; Surma et al., 2023). In contrast, acute high-dose exposure, especially from energy drinks and concentrated stimulant products, may increase blood pressure, provoke sympathetic overstimulation, and contribute to electrocardiographic changes such as QTc prolongation in susceptible individuals (Mandato et al., 2025; Voskoboinik et al., 2019). These effects are modified by individual metabolic variability, especially CYP1A2-related differences, lifestyle factors, baseline tolerance, and co-exposures (Cornelis et al., 2006; Palatini et al., 2009). Overall, the cardiovascular effects of caffeine are best understood as dose dependent, context dependent, and biologically heterogeneous. Moderate intake appears generally safe for most healthy adults, whereas high-dose products warrant greater caution and more personalized guidance.

References

Caldeira, D., Martins, C., Alves, L. B., Pereira, H., Ferreira, J. J., & Costa, J. (2013). Caffeine does not increase the risk of atrial fibrillation: A systematic review and meta-analysis of observational studies. Heart, 99(19), 1383–1389. https://doi.org/10.1136/heartjnl-2013-303950

Cheng, M., Hu, Z., Lu, X., Huang, J., & Gu, D. (2014). Caffeine intake and atrial fibrillation incidence: Dose-response meta-analysis of prospective cohort studies. Canadian Journal of Cardiology, 30(4), 448–454. https://doi.org/10.1016/j.cjca.2014.01.026

Chieng, D., Canovas, R., Segan, L., Sugumar, H., Voskoboinik, A., Prabhu, S., Ling, L.-H., Lee, G., Morton, J. B., Kaye, D. M., Kalman, J. M., & Kistler, P. M. (2022). The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: Long-term outcomes from the UK Biobank. European Journal of Preventive Cardiology, 29(17), 2240–2249. https://doi.org/10.1093/eurjpc/zwac189

Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006). Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA, 295(10), 1135–1141. https://doi.org/10.1001/jama.295.10.1135

Grosso, G., Godos, J., Galvano, F., & Giovannucci, E. L. (2017). Coffee, caffeine, and health outcomes: An umbrella review. Annual Review of Nutrition, 37, 131–156. https://doi.org/10.1146/annurev-nutr-071816-064941

Hamad, A. K. S. (2024). Caffeine and arrhythmias: A critical analysis of cardiovascular responses and arrhythmia susceptibility. Journal of the Saudi Heart Association, 36(4), 335–348. https://doi.org/10.37616/2212-5043.1402

Mandato, J., Kola, R., Tyson, T., Laffin, L., & Bales, R. (2025). The effects of energy drinks on the cardiovascular system: A systematic review. Current Cardiology Reports, 27(1), 156. https://doi.org/10.1007/s11886-025-02293-w

Marcinek, K., Luzak, B., & Rozalski, M. (2024). The effects of caffeine on blood platelets and the cardiovascular system through adenosine receptors. International Journal of Molecular Sciences, 25(16), 8905. https://doi.org/10.3390/ijms25168905

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., Stewart, L. A., Thomas, J., Tricco, A. C., Welch, V. A., Whiting, P., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, Article n71. https://doi.org/10.1136/bmj.n71

Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., & Santonastaso, M. (2009). CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. Journal of Hypertension, 27(8), 1594–1601. https://doi.org/10.1097/HJH.0b013e32832ba850

Poole, R., Kennedy, O. J., Roderick, P., Fallowfield, J. A., Hayes, P. C., & Parkes, J. (2017). Coffee consumption and health: Umbrella review of meta-analyses of multiple health outcomes. BMJ, 359, Article j5024. https://doi.org/10.1136/bmj.j5024

Shechter, M., Shalmon, G., Scheinowitz, M., Koren-Morag, N., Feinberg, M. S., Harats, D., Sela, B. A., Sharabi, Y., & Chouraqui, P. (2011). Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease. The American Journal of Cardiology, 107(9), 1255–1261. https://doi.org/10.1016/j.amjcard.2010.12.035

Stevens, L. M., Linstead, E., Hall, J. L., & Kao, D. P. (2021). Association between coffee intake and incident heart failure risk: A machine learning analysis of the Framingham Heart Study, the ARIC Study, and the CHS. Circulation: Heart Failure, 14(2), Article e006799. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006799

Surma, S., Romańczyk, M., Filipiak, K. J., & Lip, G. Y. H. (2023). Coffee and cardiac arrhythmias: Update review of the literature and clinical studies. Cardiology Journal, 30(4), 654–667. https://doi.org/10.5603/CJ.a2022.0076

Voskoboinik, A., Koh, Y., & Kistler, P. M. (2019). Cardiovascular effects of caffeinated beverages. Trends in Cardiovascular Medicine, 29(6), 345–350. https://doi.org/10.1016/j.tcm.2018.09.019

Zhao, W., Ma, L., Cai, C., & Gong, X. (2019). Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK/NF-κB signaling and A2aR signaling in LPS-induced THP-1 macrophages. International Journal of Biological Sciences, 15(8), 1571–1581. https://doi.org/10.7150/ijbs.34211